Naslov
PARP inhibitors in the treatment of the ovarian cancer

Autori
Silovski, Tajana ; Lonjak, Nikolina ; Šitić, Sanda

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Libri oncology / - , 2021, 22-23

Skup
3rd Regional Congress of Medical Oncology

Mjesto i datum
Sarajevo, Bosna i Hercegovina, 07.05.2021. - 09.05.2021

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
ovarian cancer, PARP inhibitor, BRCA mutation, HR deficiency

Sažetak
Treatment of the ovarian cancer was until recently based on initial cytoreductive surgery followed by chemotherapy based on carboplatin and paclitaxel. Based on the results of randomized phase III trials GOG-0218 and ICON7 which confirmed progression-free survival (PFS) benefit with addition of bevacizumab to chemotherapy, this combination become standard especially in high-risk patients with poor prognosis like stage IV disease, residual disease after suboptimal debulking or presence of ascites where quick response to the therapy is needed. Only few years ago the recurrent ovarian cancer treatment has changed enormously due to introduction of PARP inhibitors which were found to be effective in tumors with defects in DNA damage repair.PARP inhibitors therefore play a pivotal role in the management of newly diagnosed ovarian cancer, which will then affect subsequent treatment choices. In newly diagnosed ovarian cancer sensitivity to PARP inhibitors rely more on BRCA and HR deficiency (HRD). New data support use of PARP inhibitors earlier in the treatment algorithm.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA